EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

Determinants of early change in serum creatinine after initiation of dolutegravir‐based antiretroviral therapy in South Africa

Rephaim Mpofu iD, Aida N Kawuma iD, Roeland E Wasmann iD, Godspower Akpomiemie iD, Nomathemba Chandiwana iD, Simiso Mandisa Sokhela iD, Michelle Moorhouse iD, Willem Daniel Francois Venter iD, Paolo Denti iD, Lubbe Wiesner iD, Frank A Post iD, David W Haas iD und 2 weitere

British Journal of Clinical Pharmacology · 2024-05 · 90 (5) · 1247-1257

DOI: 10.1111/bcp.16009 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift British Journal of Clinical Pharmacology, online erschienen am 08.02.2024. Verfasst von Rephaim Mpofu und 13 weiteren Autor:innen. Beteiligte Einrichtung: Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa. Hauptthemen laut MEDLINE: Pyridones, Oxazines, Heterocyclic Compounds, 3-Ring, Piperazines. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCATS NIH HHS, NHLBI NIH HHS, Wellcome Trust.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Dolutegravir increases serum creatinine by inhibiting its renal tubular secretion and elimination. We investigated determinants of early changes in serum creatinine in a southern African cohort starting first‐line dolutegravir‐based antiretroviral therapy (ART).

Methods

We conducted a secondary analysis of data from participants in a randomized controlled trial of dolutegravir, emtricitabine and tenofovir disoproxil fumarate (TDF) or tenofovir alafenamide fumarate (TAF) (ADVANCE, NCT03122262). We assessed clinical, pharmacokinetic and genetic factors associated with change in serum creatinine from baseline to Week 4 using linear regression models adjusted for age, sex, baseline serum creatinine, HIV‐1 RNA concentration, CD4 T‐cell count, total body weight and co‐trimoxazole use.

Results

We included 689 participants, of whom 470 had pharmacokinetic data and 315 had genetic data. Mean change in serum creatinine was 11.3 (SD 9.9) μmol.L −1 . Factors that were positively associated with change in serum creatinine at Week 4 were increased log dolutegravir area under the 24‐h concentration–time curve (change in creatinine coefficient [ β ] = 2.78 μmol.L −1 [95% confidence interval (CI) 0.54, 5.01]), TDF use ( β = 2.30 [0.53, 4.06]), male sex ( β = 5.20 [2.92, 7.48]), baseline serum creatinine ( β = −0.22 [−0.31, −0.12]) and UGT1A1 rs929596 A→G polymorphism with a dominant model ( β = −2.33 [−4.49, −0.17]). The latter did not withstand correction for multiple testing.

Conclusions

Multiple clinical and pharmacokinetic factors were associated with early change in serum creatinine in individuals initiating dolutegravir‐based ART. UGT1A1 polymorphisms may play a role, but further research on genetic determinants is needed.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PyridonesOxazinesHeterocyclic Compounds, 3-RingPiperazinesCreatinineHIV InfectionsHumansMaleFemaleAdultSouth AfricaMiddle AgedGlucuronosyltransferaseAnti-HIV AgentsHIV-1HIV Integrase InhibitorsTenofovirEmtricitabinePolymorphism, Single NucleotideUGT1A1 EnzymeDolutegravir

Stichwörter der Autor:innen

HIV/AIDScytochrome P450 enzymesdrug transporterspharmacogenomicspharmacokinetic‐pharmacodynamic

Substanzen

PyridonesOxazinesHeterocyclic Compounds, 3-RingPiperazinesCreatinineGlucuronosyltransferaseAnti-HIV AgentsHIV Integrase InhibitorsTenofovirEmtricitabine

Autor:innen und Institutionen

  • Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa.
  • Ezintsha, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
  • King's College Hospital NHS Foundation Trust, London, UK.
  • Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
  • Department of Internal Medicine, Meharry Medical College, Nashville, Tennessee, USA.
  • SAMRC/UCT Platform for Pharmacogenomics Research and Translation (PREMED) unit, Cape Town, South Africa.

ORCID-Profile: Rephaim Mpofu, Aida N Kawuma, Roeland E Wasmann, Godspower Akpomiemie, Nomathemba Chandiwana, Simiso Mandisa Sokhela, Michelle Moorhouse, Willem Daniel Francois Venter, Paolo Denti, Lubbe Wiesner, Frank A Post, David W Haas, Gary Maartens, Phumla Sinxadi

Förderung

  • NCATS NIH HHS
  • NHLBI NIH HHS
  • Wellcome Trust
  • NIAID NIH HHS
  • FIC NIH HHS
  • Wellcome Centre for Infectious Diseases Research in Africa
  • Fogarty International Center
  • National Institute of Allergy and Infectious Diseases

Zitieren

APA

Mpofu, R., Kawuma, A. N., Wasmann, R. E., Akpomiemie, G., Chandiwana, N., Sokhela, S. M., Moorhouse, M., Venter, W. D. F., Denti, P., Wiesner, L., Post, F. A., Haas, D. W., Maartens, G., & Sinxadi, P. (2024). Determinants of early change in serum creatinine after initiation of dolutegravir‐based antiretroviral therapy in South Africa. British Journal of Clinical Pharmacology, 90(5), 1247-1257. https://doi.org/10.1111/bcp.16009

Vancouver

Mpofu R, Kawuma AN, Wasmann RE, Akpomiemie G, Chandiwana N, Sokhela SM, et al. Determinants of early change in serum creatinine after initiation of dolutegravir‐based antiretroviral therapy in South Africa. British Journal of Clinical Pharmacology. 2024;90(5):1247-1257. doi:10.1111/bcp.16009

BibTeX
@article{Mpofu2024,
  author = {Mpofu, Rephaim and Kawuma, Aida N and Wasmann, Roeland E and Akpomiemie, Godspower and Chandiwana, Nomathemba and Sokhela, Simiso Mandisa and Moorhouse, Michelle and Venter, Willem Daniel Francois and Denti, Paolo and Wiesner, Lubbe and Post, Frank A and Haas, David W and Maartens, Gary and Sinxadi, Phumla},
  title = {Determinants of early change in serum creatinine after initiation of dolutegravir‐based antiretroviral therapy in South Africa},
  journal = {British Journal of Clinical Pharmacology},
  year = {2024},
  volume = {90},
  number = {5},
  pages = {1247--1257},
  doi = {10.1111/bcp.16009}
}
Kostenlos starten →